.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Healthtrust
Cantor Fitzgerald
Novartis
Colorcon
Dow
US Department of Justice
QuintilesIMS
McKinsey
Fuji

Generated: December 12, 2017

DrugPatentWatch Database Preview

XOPENEX Drug Profile

« Back to Dashboard

Which patents cover Xopenex, and what generic alternatives are available?

Xopenex is a drug marketed by Oak Pharms Inc and Sunovion and is included in two NDAs. There are three patents protecting this drug and three Paragraph IV challenges.

The generic ingredient in XOPENEX is levalbuterol tartrate. There are nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the levalbuterol tartrate profile page.

Summary for XOPENEX

Drug patent expirations by year for XOPENEX

Pharmacology for XOPENEX

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-003Jan 30, 2002ANRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-004Jul 18, 2003ANRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-001Mar 25, 1999ANRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-004Jul 18, 2003ANRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-003Jan 30, 2002ANRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-001Mar 25, 1999ANRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-002Mar 25, 1999ANRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-002Mar 25, 1999ANRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: XOPENEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-004Jul 18, 2003► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-004Jul 18, 2003► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-001Mar 25, 1999► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-004Jul 18, 2003► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-004Jul 18, 2003► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-001Mar 25, 1999► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-003Jan 30, 2002► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-004Jul 18, 2003► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-002Mar 25, 1999► Subscribe► Subscribe
Oak Pharms IncXOPENEXlevalbuterol hydrochlorideSOLUTION;INHALATION020837-002Mar 25, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for XOPENEX

Drugname Dosage Strength RLD Submissiondate
levalbuterol tartrateInhalation Aerosol0.045 mg/actuationXopenex2/27/2012
levalbuterol hydrochlorideInhalation Solution0.0025Xopenex5/23/2006
levalbuterol hydrochlorideInhalation Solution0.0103%, 0.021% and 0.042%Xopenex6/20/2005

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Farmers Insurance
Colorcon
Covington
Healthtrust
Express Scripts
Medtronic
McKinsey
UBS
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot